ReviewInternational journal of molecular sciences2022
Neuroimaging Modalities in Alzheimer's Disease: Diagnosis and Clinical Features.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A systematic review of brain health in adults with chronic pain.Anaesthesia · 2026Pooled it
- Neuroimaging Insights into the Public Health Burden of Neuropsychiatric Disorders: A Systematic Review of Electroencephalography-Based Cognitive Biomarkers.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Neural correlates of subjective cognitive decline in Alzheimer's disease: a systematic review of structural and functional brain changes for early diagnosis and intervention.Frontiers in aging neuroscience · 2025Pooled it
- Comparative Diagnostic Performance of Amyloid-β Positron Emission Tomography and Magnetic Resonance Imaging in Alzheimer's Disease: A Head-to-Head Meta-Analysis.Brain and behavior · 2024Pooled it
- Artificial Intelligence for Alzheimer's Disease Diagnosis: From Traditional Machine Learning to Large Language Models.Biosensors · 2026Review
- A dynamic risk prediction framework for Alzheimer's disease and related dementias with interpretability.NPJ digital medicine · 2026Article
- Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer's disease risk.The journal of nutrition, health & aging · 2026Article
- Neuroimaging PheWAS and molecular phenotyping implicate PSMC3 in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Chemical exchange saturation transfer MRI for neurodegenerative diseases: An update on clinical and preclinical studies.Neural regeneration research · 2026Article
- Exploratory RNA Sequencing Reveals Systemic Metabolic Dysregulation in Alzheimer's Disease: Insights from a Diverse Latin American Cohort.Molecular neurobiology · 2026Article
- An interpretable multimodal ensemble assessment framework for Alzheimer's disease cognitive staging.Frontiers in neurology · 2026Article
- Pre-analytical characterization of CNS-derived extracellular vesicles from human saliva: effect of room temperature and cellular origin.Frontiers in neuroscience · 2026Article
- Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea) · 2026Article
- Adaptive Integration of Incomplete Multimodal 3D Neuroimaging for Alzheimer's Prediction and Biomarker Discovery.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- A Self-Explainable Dynamic Risk Monitoring Framework for Predicting Alzheimer's Disease and Related Dementias.medRxiv : the preprint server for health sciences · 2025Article
- Nanomedicine-Driven Modulation of the Gut-Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer's and Parkinson's Disease.International journal of molecular sciences · 2025Review
- Neuroimaging PheWAS and molecular phenotyping implicatemedRxiv : the preprint server for health sciences · 2025Article
- Trajectories of Alzheimer's Disease Prevalence among National Health Insurance and Medical Aid Beneficiaries from 2010 to 2019.Yonsei medical journal · 2025Article
- A Systems Biology Approach to Memory Health: Integrating Network Pharmacology, Gut Microbiota, and Multi-Omics for Health Functional Foods.International journal of molecular sciences · 2025Review
- BrainEpilepsia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease causing progressive cognitive decline until eventual death. AD affects millions of individuals worldwide in the absence of effective treatment options, and its clinical causes are still uncertain. The onset of dementia symptoms indicates severe neurodegeneration has already taken place. Therefore, AD diagnosis at an early stage is essential as it results in more effective therapy to slow its progression. The current clinical diagnosis of AD relies on mental examinations and brain imaging to determine whether patients meet diagnostic criteria, and biomedical research focuses on finding associated biomarkers by using neuroimaging techniques. Multiple clinical brain imaging modalities emerged as potential techniques to study AD, showing a range of capacity in their preciseness to identify the disease. This review presents the advantages and limitations of brain imaging modalities for AD diagnosis and discusses their clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.